PE20001095A1 - COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES - Google Patents
COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASESInfo
- Publication number
- PE20001095A1 PE20001095A1 PE1999001013A PE00101399A PE20001095A1 PE 20001095 A1 PE20001095 A1 PE 20001095A1 PE 1999001013 A PE1999001013 A PE 1999001013A PE 00101399 A PE00101399 A PE 00101399A PE 20001095 A1 PE20001095 A1 PE 20001095A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- conr6r7
- nr6r7
- Prior art date
Links
- 230000000172 allergic effect Effects 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 abstract 2
- 206010011224 Cough Diseases 0.000 abstract 1
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 abstract 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000002249 decongestive effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000003172 expectorant agent Substances 0.000 abstract 1
- 230000003419 expectorant effect Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229960005127 montelukast Drugs 0.000 abstract 1
- 125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 abstract 1
- 229960004583 pranlukast Drugs 0.000 abstract 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 229960004764 zafirlukast Drugs 0.000 abstract 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 abstract 1
- 229960005332 zileuton Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMBINACION FARMACEUTICA QUE COMPRENDE: a)1mg A 1OOOmg POR DOSIS UNITARIA DE UN ANTAGONISTA DE LA NEUROQUININA DE FORMULA I, DONDE Z ES EL GRUPO a O b; B ES OR2, NR6COR2, CONR6R7 O NR2CONR6R7; m ES 0-1, P Y Q SON R5-ARILO, R5-HETEROARILO; Y ES H, CR2R3CO2R6, CR2R3CONR6R7 o CR2R3NR6COR2; a Y b SON 0-2; Q Y P PUEDEN SER IGUALES O DIFERENTES; A ES =N-OR1, =N-NR2R3, =CR1R2; X ES O, NR6, N(R6)CO, CONR6; T ES R4-ARILO, R4-HETEROARILO, R4-CICLOALQUILO, R2-CICLOALQUILO; R1 ES H, ALQUILO C1-C6 o (CH2)n-G; n ES 1-6; G ES H, R4-ARILO, R4-HETEROARILO, COR6, CO2R6, CONR6R7, CN, OCOR6, SO3R2, ENTRE OTROS; R2 Y R3 SON H, ALQUILO C1-C6; R4 Y R5 SON OR2, OC(O)R2, OC(O)NR6R7, ALQUILO C1-C6, H, HALOGENO, CF3, C2F5, OCF3; R6 Y R7 SON H, ALQUILO C1-C6, CUANDO R6 Y R7 SON NR6R7 FORMAN UN ANILLO C5-C6 CON O, S, NR2, ENTRE OTROS; b)DE 2mg A 500mg DE UN ANTAGONISTA DE LEUCOTRIENO TAL COMO MONTELUKAST, PRANLUKAST, ZAFIRLUKAST; c)2mg A 5OOmg DE UN INHIBIDOR DE 5-LIPOOXIGENASA TAL COMO ZILEUTON, ATRELUTON; d)UNO O MAS PORTADORES FARMACEUTICAMENTE ACEPTABLES, UN DESCONGESTIVO, UN SUPRESOR DE LA TOSO O UN EXPECTORANTE. LA COMBINACION FARMACEUTICA ES UTIL PARA EL TRATAMIENTO DEL ASMA, RINITIS ALERGICA, ESTORNUDOSIT REFERS TO A PHARMACEUTICAL COMBINATION THAT INCLUDES: a) 1mg TO 1OOOmg PER UNIT DOSE OF AN ANTAGONIST OF FORMULA I NEUROQUININ, WHERE Z IS THE GROUP a OR b; B IS OR2, NR6COR2, CONR6R7 OR NR2CONR6R7; m IS 0-1, P AND Q ARE R5-ARYL, R5-HETEROARYL; Y IS H, CR2R3CO2R6, CR2R3CONR6R7 or CR2R3NR6COR2; a AND b ARE 0-2; Q AND P MAY BE THE SAME OR DIFFERENT; A ES = N-OR1, = N-NR2R3, = CR1R2; X IS O, NR6, N (R6) CO, CONR6; T IS R4-ARYL, R4-HETEROARYL, R4-CYCLOALKYL, R2-CYCLOALKYL; R1 IS H, C1-C6 ALKYL or (CH2) n-G; n IS 1-6; G IS H, R4-ARYL, R4-HETEROARYL, COR6, CO2R6, CONR6R7, CN, OCOR6, SO3R2, AMONG OTHERS; R2 AND R3 ARE H, C1-C6 ALKYL; R4 AND R5 ARE OR2, OC (O) R2, OC (O) NR6R7, C1-C6 ALKYL, H, HALOGEN, CF3, C2F5, OCF3; R6 AND R7 ARE H, C1-C6 ALKYL, WHEN R6 AND R7 ARE NR6R7 THEY FORM A C5-C6 RING WITH O, S, NR2, AMONG OTHERS; b) FROM 2mg TO 500mg OF A LEUCOTRIENE ANTAGONIST SUCH AS MONTELUKAST, PRANLUKAST, ZAFIRLUKAST; c) 2mg TO 5OOmg OF A 5-LIPOOXIGENASE INHIBITOR SUCH AS ZILEUTON, ATRELUTON; d) ONE OR MORE PHARMACEUTICALLY ACCEPTABLE CARRIERS, A DECONGESTIVE, A COUGH SUPPRESSOR OR AN EXPECTORANT. THE PHARMACEUTICAL COMBINATION IS USEFUL FOR THE TREATMENT OF ASTHMA, ALLERGIC RHINITIS, SLEEPING
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16960998A | 1998-10-09 | 1998-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20001095A1 true PE20001095A1 (en) | 2000-10-31 |
Family
ID=22616408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999001013A PE20001095A1 (en) | 1998-10-09 | 1999-10-06 | COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1119372A1 (en) |
| JP (1) | JP2002527406A (en) |
| CN (1) | CN1329505A (en) |
| AR (1) | AR020741A1 (en) |
| AU (1) | AU6391199A (en) |
| CA (1) | CA2346228A1 (en) |
| CO (1) | CO5140080A1 (en) |
| PE (1) | PE20001095A1 (en) |
| WO (1) | WO2000021564A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7560559B2 (en) * | 2003-04-15 | 2009-07-14 | Merck & Co., Inc. | Polymorphic form of montelukast sodium |
| BRPI0513351A (en) * | 2004-07-14 | 2008-05-06 | Inflammation Res Ct Company Lt | methods for inhibiting tumor metastasis, and inhibiting tumor cell adhesion to endothelial cells and / or inhibiting capillary permeability in the form of transendothelial migration of tumor cells, screening method for a tumor cell capillary permeability inhibitor, and, use of a leukotriene antagonist or a pharmaceutically acceptable salt thereof |
| KR20090112722A (en) | 2007-01-24 | 2009-10-28 | 글락소 그룹 리미티드 | 3,5-diamino-6- (2,3-dichlorophenyl) -1,2,4-triazine or R (-)-2,4-diamino-5- (2,3-dichlorophenyl)- Pharmaceutical composition comprising 6-fluoromethyl pyrimidine and NX1 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9415997D0 (en) * | 1994-08-08 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
| CN1160115C (en) * | 1994-12-12 | 2004-08-04 | 奥默罗斯公司 | Rinse and method for suppressing pain, inflammation and spasm |
| US5688960A (en) * | 1995-05-02 | 1997-11-18 | Schering Corporation | Substituted oximes, hydrazones and olefins useful as neurokinin antagonists |
| US5696267A (en) * | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| GB9521781D0 (en) * | 1995-10-24 | 1996-01-03 | Merck Sharp & Dohme | Therapeutic agents |
-
1999
- 1999-10-06 PE PE1999001013A patent/PE20001095A1/en not_active Application Discontinuation
- 1999-10-06 JP JP2000575537A patent/JP2002527406A/en not_active Withdrawn
- 1999-10-06 AU AU63911/99A patent/AU6391199A/en not_active Abandoned
- 1999-10-06 CO CO99063418A patent/CO5140080A1/en unknown
- 1999-10-06 EP EP99951477A patent/EP1119372A1/en not_active Withdrawn
- 1999-10-06 CA CA002346228A patent/CA2346228A1/en not_active Abandoned
- 1999-10-06 CN CN99814057A patent/CN1329505A/en active Pending
- 1999-10-06 WO PCT/US1999/021438 patent/WO2000021564A1/en not_active Ceased
- 1999-10-07 AR ARP990105083A patent/AR020741A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR020741A1 (en) | 2002-05-29 |
| AU6391199A (en) | 2000-05-01 |
| EP1119372A1 (en) | 2001-08-01 |
| CO5140080A1 (en) | 2002-03-22 |
| CA2346228A1 (en) | 2000-04-20 |
| JP2002527406A (en) | 2002-08-27 |
| WO2000021564A1 (en) | 2000-04-20 |
| CN1329505A (en) | 2002-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY27774A1 (en) | METALOPROTEIN INHIBITORS OF TRIARIL-OXI-ARIL-ESPIROPIRIMIDINA-2,4,6-TRIONA | |
| BR0112756A (en) | Compound, pharmaceutical composition, methods for treating prostaglandin-mediated diseases, nasal congestion, allergic asthma, and allergic rhinitis, and use of a compound | |
| AR016429A1 (en) | COMPOUND DERIVED FROM HYDROXAMIC ACID AS MATRIX METALOPROTEASE (MMP) INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND VETERINARY FORMULATIONS, USOPARES THE PREPARATION OF COMPOSITIONS AND FORMULATIONS, INTERMEDIARY COMPOUND, PROCEDURE FOR PREPARATION OF COMPOSITION. | |
| AR032436A1 (en) | SUBSTITUTED OXAZOLIDINONES, PROCEDURE FOR PREPARATION, MEDICINES, THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES, AND THE METHOD TO PREVENT IN VITRO BLOOD COAGULATION | |
| NO20093464L (en) | New drug mixtures based on anti-cholinergically effective compounds and beta-mimetics | |
| CY1115289T1 (en) | Methods of Treatment Against Inflammation-Related Illness | |
| CL2004000174A1 (en) | COMPOUNDS DERIVED FROM MALONAMIDE N, N'-DISUSTITUTED; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF ALZHEIMER'S DISEASE. | |
| UY28692A1 (en) | NEW DERIVATIVES OF QUINOLINA | |
| PE20050522A1 (en) | DERIVATIVES OF PIPERIDIN-2-ONA 1,6-DISUSTITUTED AS ANTAGONISTS OF THE EP4 RECEPTOR | |
| DOP2007000079A (en) | CONDENSED HETEROCYCLIC FENIL AMIDO COMPOUNDS | |
| BR0007778A (en) | Peptidyl heterocyclic ketones useful as tryptase inhibitors | |
| PE20090510A1 (en) | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | |
| UY28578A1 (en) | AMIDA DERIVATIVES | |
| CR7743A (en) | NEW OXAZOL AND TIAZOL COMPOUNDS AS INHIBITOR OF THE TRANSFORMING GROWTH FACTOR (TGF) | |
| UY26455A1 (en) | 2,4-DIAMINO-PIRIMIDINE COMPOUNDS USEFUL AS IMMUNITY SUPPRESSANTS | |
| NO20051692L (en) | Use of indolyl derivatives for the manufacture of a medicament for the treatment of allergic rhinitis | |
| DE602004012418D1 (en) | PIPERAZINE DERIVATIVES AND METHOD OF USE | |
| UY26889A1 (en) | PHARMACEUTICAL COMPOUNDS | |
| GT200100201A (en) | DERIVATIVES OF PIRAZOL FOR THE TREATMENT DER VIRIC DISEASES. | |
| ECSP19020742A (en) | CHROMANE, ISOCROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF mGluR2, COMPOSITIONS AND THEIR USE | |
| BR112022011284A2 (en) | TOPICAL COMPOSITION AND METHODS OF MEASURING THE COOLING CAPACITY OF A TOPICAL COMPOSITION | |
| DE602004028574D1 (en) | COMPOSITIONS AND METHODS FOR TREATING IRRITATION SYNDROME AND NONULCEREOUS DYSPEPSY | |
| PE20001095A1 (en) | COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES | |
| CL2020000096A1 (en) | Use of wx-uk1 and its prodrug, wx-671, for the treatment of non-cancerous diseases. | |
| ATE373644T1 (en) | N-SUBSTITUTED 3-HYDROXY-4-PYRIDINONES AND PHARMACEUTICS CONTAINING SAME |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |